-
Bayer’s Prostate Cancer Drug Nubeqa on Track to Generate Blockbuster Sales in...
22 Mar 2024 16:09 GMT
… Thursday, tipping the drug to achieve blockbuster status … eligible for treatment.
In 2022, Bayer identified approvals … for Xarelto (rivaroxaban), the anticoagulant medication that generated revenues … is a freelance pharmaceutical and biotech writer based in …
-
Bayer’s Veozah Rival Hits Goals in Long-Term Phase III Hot Flash Study
19 Mar 2024 16:55 GMT
… filings.
The clinical trial evaluated the safety and … clinical trials in applications for approval. If Bayer wins … FDA approved Veozah for the treatment of vasomotor symptoms, the medical … rivaroxaban).
Nick Paul Taylor is a freelance pharmaceutical and biotech …
-
Overview of Pharmacological Treatment in Peripheral Artery Disease
18 Mar 2024 17:54 GMT
… The phase 3 CHARISMA trial (NCT00050817) showed some … Rivaroxaban (Xarelto; Janssen Pharmaceuticals), a direct oral anticoagulant, is FDA approved … is another medication approved for the treatment of PAD … monitor for antiplatelet and statin therapy in all …
-
Bayer Korea charts new course under 1st Korean leader Lee Jin-a
18 Mar 2024 01:41 GMT
… multinational pharmaceutical company.
Lee, who joined Bayer Korea … at Bayer Korea, Lee helped Xarelto (ingredient: rivaroxaban) … across regulatory affairs, medical, marketing, and … treatment of type 2 diabetes patients with chronic kidney disease.
The drug …
-
Drugmakers submit counteroffers to US Medicare pricing negotiations
06 Mar 2024 12:22 GMT
… that all ten pharmaceutical manufacturers taking part in the Medicare drug price negotiations … (empagliflozin), and Johnson & Johnson’s Stelara (ustekinumab) and Xarelto (rivaroxaban).
According to …
-
Bayer CEO pulls back from breakup of ‘badly broken’ group
06 Mar 2024 14:49 GMT
… the group into its constituent pharmaceutical, consumer health, and … comments came just after Bayer announced that it had … years with anticoagulant Xarelto (rivaroxaban) and ophthalmic disease therapy … its fourth-quarter update, Bayer reported 2023 full-year …
-
Drug Price Negotiations Could Discourage Additional Approvals: Study
06 Mar 2024 07:13 GMT
… drug prices, the law might unintentionally discourage pharmaceutical … treatment for conditions other than its initial purpose.
The IRA’s Medicare Drug … initial FDA approval, those that required whole new trials … by the IRA. “Rivaroxaban’s indication to reduce …
-
Pharma’s Medicare counteroffers are all in, says HHS
05 Mar 2024 13:07 GMT
… aspart)
Johnson & Johnson’s Stelara (ustekinumab)
Johnson & Johnson’s Xarelto (rivaroxaban)
Becerra … lawsuit brought by the Pharmaceutical Research and Manufacturers of … care through Medicare Part D, a voluntary outpatient prescription drug benefit. …
-
Bayer pays $310m for Euro rights to ATTR therapy acoramidis
04 Mar 2024 12:14 GMT
… improving cash flow generation.
Bayer has also seen some … of a phase 3 trial of its oral … Johnson & Johnson-partnered anticoagulant Factor Xa inhibitor Xarelto (rivaroxaban), its biggest-selling drug … to make this new treatment available to patients as …
-
Market cap upturn for top 20 biopharma companies with obesity drug successes in 2023
01 Mar 2024 15:42 GMT
… into Phase III trials for the treatment of obesity. Danuglipron … below form
By GlobalData
Johnson & Johnson saw a market … and Xarelto (rivaroxaban) in Medicare’s first ten drugs subject to pricing … . However, with the FDA accepting the biologics licence …